ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Using HCV Infected Organs and the Challenge of Third-Party Payers

R. Daloul, A. Michaels, L. Sobotka, T. Pesavento, K. Washburn

Comprhensive Transplant Center, The Ohio State University, Columbus, OH

Meeting: 2020 American Transplant Congress

Abstract number: D-175

Keywords: Donors, unrelated, Hepatitis C, Kidney, Liver

Session Information

Session Name: Poster Session D: Non-Organ Specific: Viral Hepatitis

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: The practice of transplanting organs from hepatitis C viremic donors (HCV NAT+) into negative recipients hinges on the ability to ensure direct acting antiviral (DAA) therapy post-transplantation. To date, DAA coverage by third party payers for acute HCV infection cannot be guaranteed. Here we report our center experience with obtaining DAA therapy via third party payers for recipients of HCV infected organs

*Methods: Patients who met center’s criteria were consented to receive HCV NAT+ organs. We utilized a team of pharmacists and reimbursement analysts with expertise in handling DAA prior authorization process. We also allocated a fund to help pay the cost of DAA therapy for patients denied coverage. HCV Polymerase Chain Reaction (PCR) was checked on day 3 after transplant then weekly until seroconversion. Prior authorization process was started upon first positive PCR

*Results: Between February and September of 2019, 28 HCV naïve patients ranging in age between 32 to 72 years received HCV NAT+ organs. 17 patients received a kidney and 11 received a liver transplant. 27 of the 28 patients had detectable HCV PCR by day 10 post-transplant. One liver transplant recipient did not seroconvert. Time to insurance approval varied with a median of 5.5 days (Min-Max: 0- 57). Median time to therapy from transplant was 28.5 days (Min-Max: 9-75). DAA therapy consisted of velpatasvir-sofosbuvir in 68% of the patients, glecaprevir-pibrentasvir in 25% and ledipasvir-sofosbuvir in 7%. Appeal was required in 35% of the kidney and 10% of the liver recipients. One kidney recipient (5%) was denied coverage and was treated via an Abbvie Patient Assistant Program. To date, 3 patients remain on therapy while 24 patients had completed 12 weeks of therapy. 14 of the 24 patients have met criteria for sustained viral response, 8 had negative 90 days PCR and 2 had detectable HCV PCR at the end of therapy. One kidney recipient had high viral load and was started on a different DAA agent. Another kidney recipient had viral load < 100 copies/ml with two negative subsequent checks and did not require further therapy. We did not observe any treatment related adverse effects, episodes of sclerosing cholestatic hepatitis, rejection, patient or graft loss

*Conclusions: Organs from NAT+ donors appear to be a safe and effective method to expand the donor pool. However, exploitation of such a resource requires commitment of third-party payers to deliver the appropriate post-transplant DAA therapy. So far, insurance appeal rates remain high and a safety net for drug coverage outside patients’ insurance remains necessary

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Daloul R, Michaels A, Sobotka L, Pesavento T, Washburn K. Using HCV Infected Organs and the Challenge of Third-Party Payers [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/using-hcv-infected-organs-and-the-challenge-of-third-party-payers/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences